The psoriatic arthritis (PsA) therapy market has become increasingly dynamic with the recent launches of several targeted agents—AbbVie’s Rinvoq and Skyrizi and UCB’s bimekizumab. Furthermore…
The type 2 diabetes (T2D) therapy market is forecast to expand through 2032, supported by polypharmacy and growing use of later-line therapies; however, loss of exclusivity for several key T2D…
Scleroderma (systemic sclerosis) (SSc) is a rare progressive autoimmune disorder characterized by skin fibrosis, systemic inflammation, and vasculopathy that can manifest as Raynaud’s phenomenon…
Vitiligo is a chronic skin depigmentation disorder characterized by the destruction or loss of function of melanocytes. Its etiology and pathophysiology are not well understood but are believed to…
Postpartum depression (PPD) refers to the depression that some women experience after childbirth. Very few drugs are approved to treat PPD; hence, the drugs used for major depressive disorder (e.g…
The demand for safe and effective obesity treatments is growing as the prevalence of obesity increases and the efficacy of approved and pipeline agents approaches that of bariatric surgery. In…
The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…
The urticaria drug market is dominated by oral medications, including steroids and second-generation, nondrowsy antihistamines, which are prescribed for both chronic inducible urticaria (CIndU) and…
Gout is a painful, systemic inflammatory condition caused by elevated serum uric acid and characterized by intermittent acute flares. Treatment of acute gout flares typically involves NSAIDs,…
Hormonal agents dominate the treatment landscape for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatments have expanded beyond metastatic castrate-…
Eosinophilic esophagitis (EoE) is a chronic, allergic inflammatory disease of the esophagus, characterized by an accumulation of eosinophils. It can cause difficulty with swallowing food and has…
The osteoporosis therapy market will experience rapid growth over the forecast period owing to the increasing prevalence of postmenopausal osteoporosis disease and the increasing uptake of Evenity…
Renal anemia is a common complication of chronic kidney disease (CKD). Although treatments—such as iron therapies, erythropoiesis-stimulating agents (ESAs), and HIF-PH inhibitors—are available…
The ovarian cancer treatment landscape has been transformed by the angiogenesis inhibitor bevacizumab and the poly ADP ribose polymerase (PARP) inhibitors Lynparza (AstraZeneca / Merck & Co.),…
Myasthenia gravis (MG) is a rare neuromuscular disorder caused by specific autoantibodies at the neuromuscular junction targeting—in most patients—acetylcholine receptors. It is characterized…